

The story of ODM-204

NIPCF 2023



Fermion Today

Fully owned subsidiary of Orion Corporation

- New chemical entities for Orion's existing and new proprietary products
- Develops, manufactures and sells active pharmaceutical ingredients (APIs)
- Markets drug product contract manufacturing services of Orion

Fermion in 2022

Net sales: EUR 122,2 million (+10 %)

• 56 % Internal, 44 % External

Main market areas are the United States, Europe, India, South Africa and Japan, > 200 customers

Ca. 30 products, both innovative and generic APIs

Head office, R&D, bench scale production, regulatory department in Espoo


Two commercial manufacturing sites: Hanko and Oulu

Personnel: ca. 380






Locations And Facility Profiles




ODM-204




- Developed as a dual CYP17 / androgen receptor inhibitor for the treatment of prostate cancer by Orion
- Process development started at Fermion 2013
- Total of 5 GMP campaigns were conducted in addition of an initial technical campaign
- Terminated 2015

The route




🖡 Fermion

Technical campaign




SM-1

- Azide-chemistry, while fine for delivering the initial batches, was not deemed to be good enough for any further scale-up.
- Extensive testing showed that Lewis acid mediated condensation of ammonia with the ketone followed by reduction of the resulting imine is possible.



• Besides this major change, the process was streamlined







INT-1

INT-2

Initial:

- 1. Dissolve INT-1 in DMSO (5x).
- 2. Add SM-2 (1.02eq.) and DIPEA (2.0 eq).
- 3. Heat to $80 \pm 5^{\circ}$ C and hold for 8h.
- 4. Add DCM (17.5x) and water (18x) at 20° C.
- 5. Water (5.37x) is added slowly with vigorous agitation.
- 6. Separate and extract aq. layer twice with DCM (7.5x).
- 7. Wash combined organics with three times with water (7.5x).
- 8. Solvent swap to CPME (7.5x).
- 9. Cool to 0°C and isolate.

Optimized:

- 1. Dissolve INT-1 in DMSO (3.7x).
- Add SM-2 (1.03eq.), DIPEA (0.3eq.) and TMSOEt (1.18eq.).
- 3. Heat to $85 \pm 5^{\circ}$ C and held for 10h.
- 4. Cool to $15 \pm 5^{\circ}$ C.
- 5. Add EtOAc (3x), toluene (1.6x).
- 6. Add water (5.4x) slowly with vigorous agitation. Seed when about 50% of the water has been added.

Fermion


- 7. Cool to $7 \pm 3^{\circ}$ C and stir for 1h.
- 8. Isolate.

47-49%, >99.8 a-%

- High volumes and poor separations solved
- What about the yield?




SnAr – reaction profile



Much over 50% yield is not possible


Different coupling chemistry



- Preliminary Buchwald-Hartwig experiments seemed promising.
- ArBr was not available at the time (10g for ~800USD).
- Corresponding aniline is readily available and cheap.
 - Probably just a matter of demand.
- Whilst sourcing need to find a method to produce ArBr for process development.


Sandmeyer

• After some experimentation the following conditions seemed suitable




Cu residues very difficult to remove

• Following a paper with catalytic copper (Tetrahedron, 66, 2010, 7418-7422)



Buchwald-Hartwig coupling




- 1. INT-1 is dissolved in anisole (5x) under nitrogen.
- 2. 4-Bromo-2-(trifluoromethyl)benzonitrile (1.1eq.), K₃PO₄ (1.75eq.) and TDA-1 (0.01eq.) are charged.
- 3. The mixture is degassed by repeated vacuum/nitrogen cycles.
- 4. Pd(OAc)₂ (0.005eq.) and rac-BINAP (0.012 eq.) are added.
- 5. The mixture is heated to 130°C over 1h and held for 2hrs.
- 6. The reaction is cooled to 75°C after which MeCN (1x) is added followed by water (4x).
- 7. The biphasic mixture is seeded if necessary and then cooled to 20°C over 2-3hrs.
- 8. The mass is further cooled to 0°C and stirred for 1-2hrs.
- 9. The mass is filtered and washed with water (3x) and cold IPA (3x).

Never scaled up ⊗


N-methylation



- Need to find alternative for NaH/DMF
- NaH is "special"
- · Considerations:
 - INT-2 has low solubility outside of "strong" solvents
 - INT-2 is difficult to purge conversion needs to be high
 - · Imidazole is much more nucleophilic than aniline
 - Stoichiometry is very important!
 - Two potential bases were identified: NaOtBu, NaHMDS
 - Small scale lab testing NaOtBu and NaHMDS ~equivalent
 - With NaOtBu all-around decomposition
 - With NaHMDS products related to elimination pathway





Addition impurity



- During the salt formation mixture of INT-3 and fumaric acid was heated to solution then concentrated by distillation (3h-5h duration)
- ~10% of addition impurity was formed during this distillation
- · Corrective action used in the GMP batches was to
 - dissolve INT-3 and fumaric acid separately
 - polish filter them separately
 - combine the solutions with seeding
 - immediately start cooling
 - -> addition impurity < 0.2 a-%

Endgame: 1st iteration






ODM-204 FUMARATE

- Large amounts of DiMeIm indicates too large MeI charge in the 1st batch
- The second charges very small at this scale
- End product quality good

| Batch | Yield (%) | Purity (a-%) |
|-------|-----------|--------------|
| 1 | 71.0 | 99.6 |
| 2 | 72.5 | 99.9 |



Endgame: 2nd iteration




ODM-204 FUMARATE

- As expected NaOtBu produced whole spectrum of degradation products
- Dosing was even more difficult


| Batch | Yield (%) | Purity (a-%) |
|-------|-----------|--------------|
| 1 | 72.7 | 98.3 |
| 2 | 77.1 | 99.2 |




Endgame: 3rd iteration



Strangely crystallized ODM-204




Endgame: 4th iteration





Further development

• Solvent change from DMF/THF to pure THF is possible – deprotonated INT-2 is highly soluble in THF





 Interestingly, excision of DMF from the process completely removed the ammonium fumarate problem


Fermion

Further development


• Overmethylation can occur with prolonged extractions due to presence of excess Mel -> introduce a quench







INT-3



INT-2

DiMelm

| Mel (eq.) | Scavenger | Scavenger | Dimeim | Dimeim |
|-----------|-----------------|--------------|----------|----------|
| | | amount (eq.) | 1h (a-%) | 18h (a-% |
| 1.5 | None | - | 0.76 | 4.30 |
| 1.5 | Diethanolamine | 0.5 | 0.21 | 0.27 |
| 1.5 | Glycine | 0.5 | 0.51 | 1.02 |
| 1.5 | Diethanolamine | 0.75 | 0.25 | 0.61 |
| 1.5 | Imidazole | 0.5 | 0.50 | 5.23 |
| 1.5 | Ethylenediamine | 0.5 | 0.51 | 1.14 |
| 1.2 | Diethanolamine | 0.3 | 0.0 | 0.57 |
| 1.5 | Morpholine | 1.0 | 0.12 | 0.10 |
| 1.5 | Piperazine | 1.0 | 0.25 | 0.28 |
| 1.2 | Morpholine | 0.3 | 0 | 0 |
| 1.45 | Morpholine | 0.4 | 0 | 0 |

Thank you



Fermion is a subsidiary of Orion Corporation

